Project Grant R21CA282618
Award Date
7/1/24
Completion Date
6/30/26
Dollars Obligated
$356K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Albuquerque, NM 87131, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $619,294 Project Grant under CFDA 93.394 - Cancer Detection and Diagnosis Research to the University of California, San Diego (UCSD) to develop slow-release CPMV-polymer blend formulations for intratumoral immunotherapy delivery. The project aims to enhance the outcomes of intratumoral immunotherapy by addressing key challenges associated with large solid tumors, high fluid pressure, and frequent dosing. Specifically, UCSD will formulate CPMV-laden...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $483,556 to the University of New Mexico Health Sciences Center to conduct research on using mesoporous silica nanoparticles (MSN) functionalized with toll-like receptor (TLR) agonists for the treatment of peritoneal metastases associated with ovarian and colorectal cancers. The key goals of this 5-year project are to define the mechanisms by which intraperitoneal delivery of the TLR...
The National Cancer Institute (NCI) awarded a $222,998 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the University of California, San Diego (UCSD) to develop a novel virus-like particle (VLP) vector for in vivo engineering of endogenous immune cells to target and kill ovarian cancer cells. The project aims to separately target and engineer T cells, NK cells, and macrophages to express an anti-mesothelin chimeric antigen receptor (CAR) that can mediate potent killing of ovarian...
The National Cancer Institute (NCI) awarded a $577,293 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the Regents of the University of Michigan to develop and test a novel multivalent small circular mRNA (circRNA) vaccine for melanoma combination immunotherapy. The goal is to create highly stable, self-adjuvanted circRNA vaccines that can elicit potent and durable antitumor T cell immunity to enhance the efficacy of immune checkpoint blockade therapy for melanoma...
This $131,220 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, will support cancer vaccine research under the Cancer Research Manpower federal grant program (CFDA 93.398). The grant recipient, Stanford University, will develop a new approach to cancer vaccination that directly reprograms cancer cells into antigen presenting cells (APCs) through mRNA-enabled cell reprogramming. Researchers aim to overcome barriers to current vaccination...
The National Cancer Institute (NCI) awarded a $649,679 Project Grant under the Cancer Biology Research program (CFDA 93.396) to The Institute for Cancer Research, a non-profit research organization located in Cheltenham, Pennsylvania. The 5-year grant, effective August 1, 2024, will fund research to determine the role of the DHX9 helicase in triggering "viral mimicry" within small cell lung cancer (SCLC) cells. The research aims to induce an antitumor immune response and enhance...
This federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $654,681 to Case Western Reserve University to develop innovative anticancer nanovaccines utilizing multifunctional ionizable lipid nanoparticles for the curative treatment of pancreatic ductal adenocarcinoma (PDAC). The key objectives are: 1) to design and develop multifunctional ionizable ELNP based peptide vaccines for effective PDAC immunotherapy; 2) to...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) totaling $630,781 is aimed at developing mRNA lipid nanoparticle (LNP) formulations and a microgel matrix system to program targeted T helper (Th1/Th2) immune responses for cancer immunotherapy. The key objectives are to: 1) optimize LNP compositions to efficiently transfect antigen-presenting cells and elicit dual Th1/Th2 immune activation profiles; 2) engineer an LNP-loaded nanofiber...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $375,134 to the University of Colorado-Denver to investigate a novel approach for reducing the off-target accumulation of chemotherapeutic nanomedicines. The key objectives are to characterize an innate immune response that can tighten healthy tissues, thereby limiting nanoparticle deposition and associated toxicity, while enabling improved delivery to tumors. The research...
This $698,456.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program supports the "Development of a Universal mRNA Vaccine Targeting APC Mutations for Colorectal Cancer Prevention" at the Sloan-Kettering Institute for Cancer Research in New York, NY. The three-year award, running from November 1, 2024 to October 31, 2027, will fund innovative research to develop a novel mRNA-based vaccine targeting...